Table 2 Clinical, and treatment related characteristics of ovarian cancer patients at TASH and SPHMMC, Addis Ababa, Ethiopia (n = 561)

FIGO Stage at diagnosis

Stage I

41(64.06%)

23(35.94%)

64(11.41%)

7.18

0.028

Stage II

78(64.46%)

43(35.54%)

121(21.57%)

Advanced

(Stage III & IV)

197(52.4%)

179(47.6%)

376(67.02%)

Histology type

Epithelial

256(54.8%)

211(45.2%)

467(83.24%)

3.39

0.335

Germ cell

30(68.18%)

14(31.82%)

44(7.84%)

Sex cord-stromal

6(54.55%)

5(45.45%)

11(1.96%)

Others

24(61.54%)

15(38.46%)

39(6.95%)

Metastasis at time of diagnosis

Yes

199(52.2%)

182(47.8%)

381(67.91%)

8.10

0.004

No

117(65.0%)

63(35.0%)

180(32.09%)

CA-125 elevated (> 35MIU/ml)

Yes

270(53.9%)

231(46.1%)

501(89.30%)

11.31

0.001

No

46(76.67%)

14(23.33%)

60(10.70%)

Comorbidity

Yes

80(52.29%)

73(47.71%)

153(27.27%)

1.39

0.237

No

236(57.8%)

172(42.2%)

408(72.73%)

HIV status

Positive

27(62.79%)

16(37.21%)

43(7.66%)

0.89

0.641

Negative

272(55.9%)

214(44.1%)

486(86.63%)

Unknown

17(53.13%)

15(46.88%)

32(5.70%)

Baseline anemia

Yes

132(57.2%)

99(42.86%)

231(41.18%)

0.110

0.745

No

184(55.8%)

146(44.3%)

330(58.82%)

Type of treatment

Chemo-surgery

211(52.6%)

190(47.4%)

401(71.48%)

10.59

0.032

Surgery

78(63.93%)

44(36.07%)

122(21.75%)

Chemotherapy

12(60.00%)

8(40.00%)

20(3.57%)

Palliative care

6(85.71%)

1(14.29%)

7(1.25%)

Others

9(81.82%)

2(18.18%)

11(1.96%)

Duration of treatment

< 19week

187(63.6%)

107(36.4%)

294(52.41%)

13.29

0.001

≥ 19week

129(48.3%)

138(51.7%)

267(47.59%)

Treatment completed

Yes

124(60.8%)

80(39.22%)

204(36.36%)

2.59

0.108

No

192(53.8%)

165(46.2%)

357(63.64%)

Residual tumor after surgery

Yes

177(52.1%)

163(47.9%)

340(64.52%)

5.95

0.051

No

82(64.57%)

45(35.43%)

127(24.10%)

Unknown

32(53.33%)

28(46.67%)

60(11.39%)

Pain medication received

Yes

136(56.4%)

105(43.6%)

241(42.96%)

0.01

0.966

No

180(56.3%)

140(43.6%)

320(57.04%)